Related Experiment Video
Updated: Nov 21, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
657
Pediatric Obesity, Hypertension, Lipids
Scott Leopold1, Justin P Zachariah1
1Section of Pediatric Cardiology, Texas Children's Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Current Treatment Options in Pediatrics
|January 18, 2021
Summary
Pediatric obesity, hypertension, and lipid disorders are rising, increasing risks for adult cardiovascular disease. Early lifestyle interventions in children can prevent long-term health issues.
Area of Science:
- Pediatric Cardiology
- Preventive Medicine
- Public Health
Background:
- The increasing prevalence of childhood obesity, hypertension, and lipid abnormalities over the last 40 years presents a significant public health challenge.
- These conditions in children are linked to premature atherosclerotic cardiovascular disease, leading to early morbidity and mortality in adulthood.
- Risk factors for cardiovascular disease often track from childhood into adulthood, highlighting the critical need for early intervention.
Purpose of the Study:
- To review the management of obesity, hypertension, and lipid abnormalities in children.
- To emphasize the importance of early prevention strategies for atherosclerotic cardiovascular disease in pediatric populations.
- To discuss the role of lifestyle modifications and therapeutic interventions in mitigating cardiovascular risk in children.
Main Methods:
- Review of multiple studies on pediatric cardiovascular risk factors.
- Analysis of the impact of individual risk factors (obesity, hypertension, lipid abnormalities) on target organ damage in children.
- Evaluation of the effectiveness of lifestyle modifications in improving subclinical disease and reducing future morbidity.
Main Results:
- Obesity, hypertension, and lipid abnormalities can occur independently in children, each contributing to target organ damage.
- Intensive and focused lifestyle modifications have demonstrated the ability to improve subclinical disease in children.
- Early intervention can significantly decrease the risk of future morbidity associated with these conditions.
Conclusions:
- Childhood represents a critical window for the primordial and primary prevention of atherosclerotic cardiovascular disease.
- Clinicians should prioritize addressing prevalent conditions like pediatric obesity, hypertension, and lipid disorders.
- A multi-faceted approach, starting with lifestyle modifications and progressing to pharmacologic or surgical therapies as necessary, is essential for effective management.
Related Concept Videos
01:24Obesity
930
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
930
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
111
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
111
01:24Overview of Lipid Metabolism
3.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.8K
01:21Drug Dosing: Obese Patients
85
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
85
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
130
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
130
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
78
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
78